Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

27 giugno 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

Philogen to the 12th European Post-Chicago Melanoma/Skin Cancer Meeting, 30-1 July

Philogen will be Bronze Sponsor of the Post-Chicago Meeting in Münich (30-1 July). Philogen will chair a Satellite Symposium on Friday July 1, 11.30-12.00 am. Dr....

Philogen to attend the 3rd Annual Cytokine-Based Drug Development Summit, Boston (July 26-29, 2022)

Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston.   Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture...

Philogen to attend the 13th World ADC San Diego 2022, San Diego, USA (6-9 September 2022)

Philogen will attend the 13th World ADC in San Diego (USA) in September 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture...

Philogen to attend EANO Congress in Vienna, Austria (15-18 September 2022)

Philogen will attend EANO Meeting in Vienna in September 2022. More details on the lecture held by Philogen will follow shortly. Please visit the EANO Meeting Website...

Philogen Provides Corporate Update

Philogen’s management team will hold a webinar to discuss these updates on June 23, 2022, at 10:00 ET / 15:00 BST / 16:00 CEST (Please find the link to this webinar...

20 giugno 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

13 giugno 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

06 giugno 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

30 maggio 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions